Table 1 Patient characteristics at diagnosis
Age at diagnosis | Years | |
|---|---|---|
Mean (range) | 69.2 (45 – 88) | |
Age at diagnosis | Number of Patients | Percent of Patients |
45–49 | 1 | 0.3 |
50–54 | 7 | 2.3 |
55–59 | 23 | 7.6 |
60–64 | 35 | 11.5 |
65–70 | 54 | 17.8 |
70–74 | 80 | 26.3 |
75–79 | 54 | 17.8 |
80–84 | 36 | 11.8 |
85-88 | 14 | 4.6 |
PSA level at diagnosis | ng/mL | |
Mean (range) | 6.08 (0.7 to 27.7) | |
Median | 5.8 | |
PSA level at diagnosis | Number of Patients | Percent of Patients |
<4 ng/mL | 59 | 19.4 |
4–10 ng/mL | 203 | 66.8 |
>10–20 ng/mL | 40 | 13.2 |
>20 ng/mL | 2 | 0.7 |
Clinical Stage | Number of Patients | Percent of Patients |
T1cN0M0 | 280 | 92.1 |
T2aN0M0 | 24 | 7.9 |
Gleason Score | Number of Patients | Percent of Patients |
= 6 | 222 | 73 |
=7 | 70 | 23 |
> 8 | 12 | 4 |
Hormone Treatment | Number of Patients | Percent of Patients |
No | 247 | 81.3 |
Yes | 57 | 18.8 |
Risk Assessment: Criteria | Number of Patients | Percent of Patients |
Low Risk: Gleason Score ≤ 6 and PSA ≤ 10 ng/ml. | 211 | 69.4 |
Intermediate Risk: Gleason = 7 or PSA > 10 and PSA < 20 | 81 | 26.6 |
High Risk: Gleason ≥ 8 or PSA > 20 | 12 | 0.7 |